|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herr HW, Dotan Z, Donat SM and Bajorin DF:
Defining optimal therapy for muscle invasive bladder cancer. J
Urol. 177:437–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dogliotti L, Carteni G, Siena S, et al:
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as
first-line chemotherapy in advanced transitional cell carcinoma of
the urothelium: results of a randomized phase 2 trial. Eur Urol.
52:134–141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burz C, Berindan-Neagoe I, Balacescu O and
Irimie A: Apoptosis in cancer: key molecular signaling pathways and
therapy targets. Acta Oncol. 48:811–821. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taylor RC, Cullen SP and Martin SJ:
Apoptosis: controlled demolition at the cellular level. Nat Rev Mol
Cell Biol. 9:231–241. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glick SH, Howell LP and White RW:
Relationship of p53 and bcl-2 to prognosis in muscle-invasive
transitional cell carcinoma of the bladder. J Urol. 155:1754–1757.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hussain SA, Ganesan R, Hiller L, et al:
BCL2 expression predicts survival in patients receiving synchronous
chemoradiotherapy in advanced transitional cell carcinoma of the
bladder. Oncol Rep. 10:571–576. 2003.PubMed/NCBI
|
|
11
|
Ong F, Moonen LM, Gallee MP, et al:
Prognostic factors in transitional cell cancer of the bladder: an
emerging role for Bcl-2 and p53. Radiother Oncol. 61:169–175. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pollack A, Wu CS, Czerniak B, Zagars GK,
Benedict WF and McDonnell TJ: Abnormal bcl-2 and pRb expression are
independent correlates of radiation response in muscle-invasive
bladder cancer. Clin Cancer Res. 3:1823–1829. 1997.PubMed/NCBI
|
|
13
|
Korkolopoulou P, Lazaris A, Konstantinidou
AE, et al: Differential expression of bcl-2 family proteins in
bladder carcinomas. Relationship with apoptotic rate and survival.
Eur Urol. 41:274–283. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eckelman BP, Salvesen GS and Scott FL:
Human inhibitor of apoptosis proteins: why XIAP is the black sheep
of the family. EMBO Rep. 7:988–994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li M, Song T, Yin ZF and Na YQ: XIAP as a
prognostic marker of early recurrence of nonmuscular invasive
bladder cancer. Chin Med J (Engl). 120:469–473. 2007.PubMed/NCBI
|
|
16
|
Velculescu VE, Madden SL, Zhang L, et al:
Analysis of human transcriptomes. Nat Genet. 23:387–388. 1999.
View Article : Google Scholar
|
|
17
|
Dohi T, Okada K, Xia F, et al: An IAP-IAP
complex inhibits apoptosis. J Biol Chem. 279:34087–34090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Margulis V, Lotan Y and Shariat SF:
Survivin: a promising biomarker for detection and prognosis of
bladder cancer. World J Urol. 26:59–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schultz IJ, Kiemeney LA, Witjes JA, et al:
Survivin mRNA expression is elevated in malignant urothelial cell
carcinomas and predicts time to recurrence. Anticancer Res.
23:3327–3331. 2003.PubMed/NCBI
|
|
20
|
Shariat SF, Ashfaq R, Karakiewicz PI,
Saeedi O, Sagalowsky AI and Lotan Y: Survivin expression is
associated with bladder cancer presence, stage, progression, and
mortality. Cancer. 109:1106–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weikert S, Christoph F, Schrader M, Krause
H, Miller K and Muller M: Quantitative analysis of survivin mRNA
expression in urine and tumor tissue of bladder cancer patients and
its potential relevance for disease detection and prognosis. Int J
Cancer. 116:100–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dallas A and Vlassov AV: RNAi: a novel
antisense technology and its therapeutic potential. Med Sci Monit.
12:RA67–74. 2006.PubMed/NCBI
|
|
23
|
Kim DH and Rossi JJ: Strategies for
silencing human disease using RNA interference. Nat Rev Genet.
8:173–184. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han Z, Chatterjee D, Early J, Pantazis P,
Hendrickson EA and Wyche JH: Isolation and characterization of an
apoptosis-resistant variant of human leukemia HL-60 cells that has
switched expression from Bcl-2 to Bcl-xL. Cancer Res. 56:1621–1628.
1996.PubMed/NCBI
|
|
25
|
Tan ML, Ooi JP, Ismail N, Moad AI and
Muhammad TS: Programmed cell death pathways and current antitumor
targets. Pharm Res. 26:1547–1560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shangary S and Johnson DE: Recent advances
in the development of anticancer agents targeting cell death
inhibitors in the Bcl-2 protein family. Leukemia. 17:1470–1481.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kunze D, Wuttig D, Fuessel S, et al:
Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2,
BCL-X(L)) in bladder cancer cells. Anticancer Res. 28:2259–2263.
2008.PubMed/NCBI
|
|
29
|
Ning S, Fuessel S, Kotzsch M, et al:
siRNA-mediated down-regulation of survivin inhibits bladder cancer
cell growth. Int J Oncol. 25:1065–1071. 2004.PubMed/NCBI
|
|
30
|
Castanotto D, Sakurai K, Lingeman R, et
al: Combinatorial delivery of small interfering RNAs reduces RNAi
efficacy by selective incorporation into RISC. Nucleic Acids Res.
35:5154–5164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang D, Song X, Zhang J, et al:
Therapeutic potential of siRNA-mediated combined knockdown of the
IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24
cells. Acta Biochim Biophys Sin (Shanghai). 42:137–144. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jeyaprakash AA, Klein UR, Lindner D, Ebert
J, Nigg EA and Conti E: Structure of a Survivin-Borealin-INCENP
core complex reveals how chromosomal passengers travel together.
Cell. 131:271–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takizawa BT, Uchio EM, Cohen JJ, Wheeler
MA and Weiss RM: Downregulation of survivin is associated with
reductions in TNF receptors’ mRNA and protein and alterations in
nuclear factor kappa B signaling in urothelial cancer cells. Cancer
Invest. 25:678–684. 2007.PubMed/NCBI
|
|
34
|
Sensintaffar J, Scott FL, Peach R and
Hager JH: XIAP is not required for human tumor cell survival in the
absence of an exogenous death signal. BMC Cancer. 10:112010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anderson EM, Miller P, Ilsley D, et al:
Gene profiling study of G3139- and Bcl-2-targeting siRNAs
identifies a unique G3139 molecular signature. Cancer Gene Ther.
13:406–414. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gallardo-Perez JC, Espinosa M,
Ceballos-Cancino G, et al: NF-kappa B is required for the
development of tumor spheroids. J Cell Biochem. 108:169–180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang TM, Barbone D, Fennell DA and
Broaddus VC: Bcl-2 family proteins contribute to apoptotic
resistance in lung cancer multicellular spheroids. Am J Respir Cell
Mol Biol. 41:14–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mu P, Nagahara S, Makita N, Tarumi Y,
Kadomatsu K and Takei Y: Systemic delivery of siRNA specific to
tumor mediated by atelocollagen: combined therapy using siRNA
targeting Bcl-xL and cisplatin against prostate cancer. Int J
Cancer. 125:2978–2990. 2009. View Article : Google Scholar
|
|
39
|
Zhu H, Guo W, Zhang L, et al: Enhancing
TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther.
4:393–397. 2005.PubMed/NCBI
|
|
40
|
Gill C, Dowling C, O’Neill AJ and Watson
RW: Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate
cancer cell susceptibility to apoptosis, cell survival and
proliferation. Mol Cancer. 8:392009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ruckert F, Samm N, Lehner AK, Saeger HD,
Grutzmann R and Pilarsky C: Simultaneous gene silencing of Bcl-2,
XIAP and Survivin re-sensitizes pancreatic cancer cells towards
apoptosis. BMC Cancer. 10:3792010. View Article : Google Scholar : PubMed/NCBI
|
